%PDF-1.4
%
89 0 obj
<>
endobj
86 0 obj
<>
endobj
145 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-05T10:50:53Z
2024-03-28T22:05:59-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:05:59-07:00
application/pdf
Heather
2001-78.jan
uuid:6f8e086d-1dd2-11b2-0a00-9c09275dc400
uuid:6f8e0870-1dd2-11b2-0a00-810000000000
endstream
endobj
75 0 obj
<>
endobj
76 0 obj
<>
endobj
90 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 61 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 63 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
41 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
44 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
175 0 obj
[179 0 R]
endobj
176 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 7.76 0 0 8 61.78 714.5293 Tm
[(3.)-515.6 (Lequesne M, Brandt K, Bellamy N, et al. Guidelines for testing slow)]TJ
1.2655 -1.25 Td
(acting drugs in osteoarthritis. J Rheumatol 1994;21 Suppl 41:65-73.)Tj
-1.2655 -1.25 Td
[(4.)-515.6 (Deyo RA, Diehr P)110.7 (, Patrick DL. Reproducibility and responsiveness of)]TJ
1.2655 -1.25 Td
(health status measures. Statistics and strategies for evaluation.)Tj
0 -1.25 TD
[(Controlled Clin )17.7 (T)35 (rials 1991;12:142S-158S.)]TJ
-1.2655 -1.25 Td
[(5.)-515.6 (Lesquesne M, M\216ry C, Samson M, G\216rard P)110.7 (. Indexes of severity for)]TJ
1.2655 -1.25 Td
(osteoarthritis of the hip and knee. Scand J Rheumatol 1987;65)Tj
0 Tw T*
(Suppl:85-9.)Tj
0.02499 Tw -1.2655 -1.25 Td
[(6.)-515.6 (Bellamy N. )17.7 (WOMAC Osteoarthritis Index. )54.8 (A)-220.1 (user)-37 (\325)55.1 (s)-0.1 ( guide. London,)]TJ
1.2655 -1.25 Td
[(Canada: University of )17.7 (W)79.9 (estern Ontario; 1995.)]TJ
-1.2655 -1.25 Td
[(7.)-515.6 (Bellamy N, Buchanan )17.7 (WW)91.7 (. )54.8 (A)-220.1 (preliminary evaluation of the)]TJ
1.2655 -1.25 Td
(dimensionality and clinical importance of pain and disability in)Tj
T*
(osteoarthritis of the hip and knee. Clin Rheumatol 1986;5:231-41.)Tj
-1.2655 -1.25 Td
[(8.)-515.6 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.9 (.)]TJ
1.2655 -1.25 Td
[(V)110.8 (alidation study of )17.7 (WOMAC: )54.8 (A)-220.1 (health status instrument for)]TJ
T*
(measuring clinically important patient relevant outcomes to)Tj
T*
(antirheumatic drug therapy in patients with osteoarthritis of the hip or\
)Tj
T*
(knee. J Rheumatol 1988;15:1833-40.)Tj
-1.2655 -1.25 Td
[(9.)-515.6 (Bellamy N. Pain assessment in osteoarthritis: experience with the)]TJ
1.2655 -1.25 Td
[(WOMAC Osteoarthritis Index. Semin )54.8 (Arthritis Rheum 1989;18 Suppl)]TJ
0 Tw T*
(2:14-7.)Tj
0.02499 Tw -1.7655 -1.25 Td
[(10.)-515.6 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Duku E.)]TJ
1.7655 -1.25 Td
[(Signal measurement strategies: are they feasible and do they of)17.7 (fer any)]TJ
T*
[(advantage in outcome measurement in osteoarthritis? )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1990;33:739-45.)Tj
-0.00011 Tc 0.02499 Tw -1.7286 -1.25 Td
[(1)36.8 (1)-0.1 (.)-515.6 (Bellamy N, Kean )17.7 (WF)79.7 (, Buchanan )17.7 (WW)91.7 (, Gerecz-Simon E, Campbell J.)]TJ
1.7286 -1.25 Td
(Double blind randomized controlled trial of sodium meclofenamate)Tj
T*
[(\(Meclomen\) and diclofenac sodium \(V)128.8 (oltaren\): post validation)]TJ
T*
[(reapplication of the )17.7 (WOMAC Osteoarthritis Index. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1992;19:153-9.)Tj
-0.00011 Tc 0.02499 Tw -1.7655 -1.25 Td
[(12.)-515.6 (Stucki G, Meier D, Stucki S, et al. Evaluation of a German version of)]TJ
1.7655 -1.25 Td
[(the )17.7 (WOMAC \(W)79.7 (estern Ontario and McMaster Universities\))]TJ
T*
(Osteoarthritis Index. Z Rheumatol 1996;55:40-9.)Tj
-1.7655 -1.25 Td
[(13.)-515.6 (Jaeschke R, Singer J, Guyatt GH. Measurement of health status.)]TJ
1.7655 -1.25 Td
[(Ascertaining the minimal clinically important dif)17.7 (ference. Controlled)]TJ
0.00729 Tw T*
[(Clin T)35 (rials )-17.7 (1989;10:407-15.)]TJ
0.02499 Tw -1.7655 -1.25 Td
[(14.)-515.6 (Hawker G, Melfi C, Paul J, Green R, Bombardier C. Comparison of a)]TJ
1.7655 -1.25 Td
(generic \(SF-36\) and a disease specific \(WOMAC\) instrument in the)Tj
T*
[(measurement of outcomes after knee replacement sur)17.7 (gery)64.8 (.)]TJ
T*
[(J Rheumatol 1995;22:1)36.8 (193-6.)]TJ
-1.7655 -1.25 Td
[(15.)-515.6 (Kantz ME, Harris )17.7 (WJ, Levitsky K, )17.7 (W)79.9 (are JE, Davies )54.8 (AR. Methods for)]TJ
1.7655 -1.25 Td
(assessing condition-specific and generic functional status outcomes)Tj
T*
(after total knee replacement. Med Care 1992;5:MS240-52.)Tj
-1.7655 -1.25 Td
[(16.)-515.6 (W)39.8 (right JG, )36.8 (Y)99.8 (oung NL. )54.8 (A)-220.1 (comparison of dif)17.7 (ferent indices of)]TJ
1.7655 -1.25 Td
(responsiveness. J Clin Epidemiol 1997;50:239-46.)Tj
32.2552 55 Td
[(17.)-515.6 (Ruof J, Sangha O, Stucki G. Comparative responsiveness of 3)]TJ
1.7655 -1.25 Td
(functional indices in ankylosing spondylitis. Rheumatol 1999;)Tj
0 Tc 0 Tw T*
(26:1959-63.)Tj
-0.00011 Tc 0.02499 Tw -1.7655 -1.25 Td
[(18.)-515.6 (Laupacis )54.8 (A, Bourne R, Rorabeck C, et al. )17.7 (The ef)17.7 (fect of elective total)]TJ
1.7655 -1.25 Td
[(hip replacement on health-related quality of life. J Bone Joint Sur)17.7 (g )54.8 (Am)]TJ
0 Tc 0 Tw T*
(1993;75:1619-26.)Tj
-0.00011 Tc 0.02499 Tw -1.7655 -1.25 Td
[(19.)-515.6 (Altman RD, Bloch DA, Bole GG Jr)39.7 (, et al. Development of criteria for)]TJ
1.7655 -1.25 Td
(osteoarthritis. J Rheumatol 1987;14 Suppl 14:3-6.)Tj
-1.7655 -1.25 Td
[(20.)-515.6 (Stucki G, Liang MH, Fossel )54.8 (AH, Katz JN. Relative responsiveness of)]TJ
1.7655 -1.25 Td
(condition-specific and generic health status measures in degenerative)Tj
T*
(lumbar spinal stenosis. J Clin Epidemiol 1995;48:1369-78.)Tj
-1.7655 -1.25 Td
[(21.)-515.6 (Stucki G, Daltroy L, Liang MH, Lipson SJ, Fossel )54.8 (AH, Katz JN.)]TJ
1.7655 -1.25 Td
(Measurement properties of a self-administered outcome measure in)Tj
T*
(lumbar spinal stenosis. Spine 1996;21:796-803.)Tj
-1.7655 -1.25 Td
[(22.)-515.6 (Redelmeier DA, Lorig K. )54.8 (Assessing the clinical importance of)]TJ
1.7655 -1.25 Td
[(symptomatic improvements. )54.8 (An illustration in rheumatology)64.8 (. )54.8 (Arch)]TJ
T*
(Intern Med 1993;153:1337-42.)Tj
-1.7655 -1.25 Td
[(23.)-515.6 (Stucki G, Liang MH, Stucki S, Katz JN, Lew RA. )54.8 (Application of)]TJ
1.7655 -1.25 Td
(statistical graphics to facilitate selection of health status measures f\
or)Tj
T*
(clinical practice and evaluative research. Clin Rheumatol)Tj
0 Tc 0 Tw T*
(1999;18:101-5.)Tj
-0.00011 Tc 0.02499 Tw -1.7655 -1.25 Td
[(24.)-515.6 (Corzillius M, Fortin P)110.7 (, Stucki G. Responsiveness and sensitivity to)]TJ
1.7655 -1.25 Td
(change of SLE disease activity measures. Lupus 1999;8:655-9.)Tj
-1.7655 -1.25 Td
[(25.)-515.6 (Ehrich EW)91.7 (, Davies GM, )17.7 (W)79.9 (atson DJ, Bolognese JA, Seidenber)17.7 (g BC,)]TJ
1.7655 -1.25 Td
(Bellamy N. Minimal perceptible clinical improvement with the)Tj
T*
[(W)79.9 (estern Ontario and McMaster Universities Osteoarthritis Index)]TJ
T*
(questionnaire and global assessments in patients with osteoarthritis. )Tj
T*
(J Rheumatol 2000;27:2635-41.)Tj
-1.7655 -1.25 Td
[(26.)-515.6 (Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT)73.9 (, )17.7 (W)79.9 (are JE. Determining)]TJ
1.7655 -1.25 Td
(minimally important changes in generic and disease-specific health-)Tj
T*
(related quality of life questionnaires in clinical trials of rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 2000;43:1478-87.)]TJ
-1.7655 -1.25 Td
[(27.)-515.6 (Kazis ES, )54.8 (Anderson JJ, Meenan RF)79.7 (. Ef)17.7 (fect sizes for interpreting)]TJ
1.7655 -1.25 Td
(changes in health status. Med Care 1989;27 Suppl:S178-89.)Tj
-1.7655 -1.25 Td
[(28.)-515.6 (Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell )54.8 (A.)]TJ
1.7655 -1.25 Td
[(Responsiveness and validity in health status measurement: )54.8 (A)]TJ
T*
(clarification. J Clin Epidemiol 1989;42:403-8.)Tj
-1.7655 -1.25 Td
[(29.)-515.6 (W)79.9 (einstein ND. Optimistic biases about personal risk. Science)]TJ
0 Tc 0 Tw 1.7655 -1.25 Td
(1989;246:1232-3.)Tj
-0.00011 Tc 0.02499 Tw -1.7655 -1.25 Td
[(30.)-515.6 (Bindman )54.8 (AB, Keane D, Lurie N. Measuring health changes among)]TJ
1.7655 -1.25 Td
[(severely ill patients. )17.7 (The floor phenomenon. Med Care 1990;)]TJ
0 Tc 0 Tw T*
[(28:1)36.9 (142-51.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(138)Tj
ET
0 0 0 0 k
/GS0 gs
102.51 59.38 407.5 -10.83 re
f*
0.5 w
102.51 59.38 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>stream
8;Z\7$#[X7%+G5@W:(.I,Ef@o`m'Y^"0>p"ZH,'TMWrp*D>R[PeirHPgtJU6lh9-'
\G>F++dt>+4lgVRGTI`,E,-o&\kM]694DID%:t`XK^g2p(eS8g!+[h%2.IE]gGud[
c&R^:im=E4GV.VPC3>DJ@2M.(1Ppd(piU">hr@i"t
IP@W9A;j$0e91'B&iA>_]21domn2p2JetpBS7_*2l18RI>2km.?.e[Ur0`e6n5?NQ
/fbe#li<9$Yn[(k0(UEoZTaZ3SKkZ\RF?C%1)1?&\-]@<*qc4+UFXcj+mZ.n^O0.,W*FRu5'"4!;U!TOC;jSQQ^q&CQ^#C`m+4&UhUP"*]75ghsV%TMbKV+\`%8QH19#SSgRVrecTb4[V@WEW%\4\t;
Zg9kK4M\Cf'11aW@Mg=A'Hc>Y]5!L"72=8X*^5*Qg@,/kW?*OSrDNY;)Z]C\',s"A
-,aS7L_R5VqkAuc9P$8W[E9Jp.^"?q]J-/JOlWK-5YbgHVZgF8+DP.k(,Y=K1ggTQ
iEGc7bp&seb)<7ndscqC-^$e_;6upucWT1$d`S0!M9@'Oo8q8,>G02^X(2R.6(#i)
OF#t0MTu*[7AlbW]5?<2D;2L9gR$/;fKE)<8%bn9pUp#jD>lcI[T!&@!!oqh`W~>
endstream
endobj
73 0 obj
[/Indexed/DeviceRGB 255 72 0 R]
endobj
72 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
97 0 obj
<>
endobj
92 0 obj
<>
endobj
128 0 obj
<>
endobj
150 0 obj
<>
endobj
93 0 obj
<>
endobj
120 0 obj
<>stream
HUiPSY~Mxͨiq+W@TFQ @@KHl& K5h*6"JcOkPs^2K35gT}u{:ߩ1[q6l#n'gv˯c}0ggڰ~;EB|G⼣-V̟?ۑ~?]|}nb$S
GN.fKribf2~;\1kS)|fD$gMYd1?0k32"&/['f"&&3s1=L K(dE\F`奈\_K%í9`.Ӱa<ı%QXtþ5bFb(l/pfFU~K>,TNJ?:889cڐj+NNNN
M++ZqtuWߠW+<=f(f<"T^M2\kH
q'vBI`fL^S$:QAfHV*U2W1_ZDB˔M'Иg6fsQ(qLo.Kg$.WF9hV샡=IuMK#瞀 KFg
ie3rɉ'S +/7